Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M707812200 on October 31, 2007

J. Biol. Chem., Vol. 283, Issue 1, 358-366, January 4, 2008
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
283/1/358    most recent
M707812200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by van der Velden, J. L. J.
Right arrow Articles by Langen, R. C. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van der Velden, J. L. J.
Right arrow Articles by Langen, R. C. J.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Glycogen Synthase Kinase 3β Suppresses Myogenic Differentiation through Negative Regulation of NFATc3*

Jos L. J. van der Velden, Annemie M. W. J. Schols, Jodil Willems, Marco C. J. M. Kelders, and Ramon C. J. Langen1

From the Department of Respiratory Medicine, Nutrition and Toxicology Research Institute Maastricht, Maastricht University, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands

Skeletal muscle atrophy is a prominent and disabling feature in many chronic diseases. Prevention or reversal of muscle atrophy by stimulation of skeletal muscle growth could be an important therapeutic strategy. Glycogen synthase kinase 3β (GSK-3β) has been implicated in the negative regulation of skeletal muscle growth. Since myogenic differentiation is an essential part of muscle growth, we investigated if inhibition of GSK-3β is sufficient to stimulate myogenic differentiation and whether this depended on regulation of the transcription factor nuclear factor of activated T-cells (NFAT). In both myogenically converted mouse embryonic fibroblasts and C2C12 myoblasts, deficiency of GSK-3β protein (activity) resulted in enhanced myotube formation and muscle-specific gene expression during differentiation, which was reversed by reintroduction of wild type but not kinase-inactive (K85R) GSK-3β. In addition, GSK-3β inhibition restored myogenic differentiation following calcineurin blockade, which suggested the involvement of NFAT. GSK-3β-deficient mouse embryonic fibroblasts or myoblasts displayed enhanced nuclear translocation of NFATc3 and elevated NFAT-sensitive promoter transactivation, which was reduced by reintroducing wild type, but not K85R GSK-3β. Overexpression of NFATc3 increased muscle gene promoter transactivation, which was abolished by co-expression of wild type GSK-3β. Finally, stimulation of muscle gene expression observed following GSK-3β inhibition was strongly attenuated in NFATc3-deficient myoblasts, indicating that this response requires NFATc3. Collectively, our data demonstrate negative regulation of myogenic differentiation by GSK-3β through a transcriptional mechanism that depends on NFATc3. Inhibition of GSK-3β may be a potential strategy in prevention or treatment of muscle atrophy.


Received for publication, September 18, 2007

* This work was supported by Netherlands Asthma Foundation Grant NAF 3.2.02.6 [EC] 3. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 To whom correspondence should be addressed. Tel.: 31-43-388-4247; Fax: 31-43-387-5051; E-mail: r.langen{at}pul.unimaas.nl.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
A. H. V. Remels, R. C. J. Langen, H. R. Gosker, A. P. Russell, F. Spaapen, J. W. Voncken, P. Schrauwen, and A. M. W. J. Schols
PPAR{gamma} inhibits NF-{kappa}B-dependent transcriptional activation in skeletal muscle
Am J Physiol Endocrinol Metab, July 1, 2009; 297(1): E174 - E183.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
V. E. Jahnke, O. Sabido, and D. Freyssenet
Control of mitochondrial biogenesis, ROS level, and cytosolic Ca2+ concentration during the cell cycle and the onset of differentiation in L6E9 myoblasts
Am J Physiol Cell Physiol, May 1, 2009; 296(5): C1185 - C1194.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
N. Stupka, J. D. Schertzer, R. Bassel-Duby, E. N. Olson, and G. S. Lynch
Stimulation of calcineurin A{alpha} activity attenuates muscle pathophysiology in mdx dystrophic mice
Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2008; 294(3): R983 - R992.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2008 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement